Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.65 |
| ▸ | CFTR | P13569 | 5/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5469359 | 0.86 | TRPV1 (0.69) | TRPV1PDK1PDK2PDK3PDK4 | |
| SCHEMBL4908258 | 0.85 | TRPV1 (0.67) | TRPV1PDK1PDK2PDK3PDK4 | |
| SCHEMBL4911389 | 0.85 | TRPV1 (0.67) | TRPV1PDK1PDK2PDK3PDK4 | |
| SCHEMBL13955128 | 0.84 | TRPV1 (0.50) | TRPV1CFTRPDK1PDK2PDK3 | |
| SCHEMBL4357351 | 0.82 | TRPV1 (0.67) | TRPV1CFTRPDK1PDK2PDK3 | |
| SCHEMBL4972843 | 0.80 | CFTR (0.58) | TRPV1CFTRPDK2 | |
| SCHEMBL5934388 | 0.79 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL4351466 | 0.79 | TRPV1 (0.53) | TRPV1CFTR | |
| SCHEMBL5934107 | 0.79 | TRPV1 (0.86) | TRPV1 | |
| SCHEMBL5934356 | 0.76 | TRPV1 (0.76) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488740-B2 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1644372-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | NEUROGEN CORPORATION | 2005-03-31 | — | — | US | disclosed |
| WO-2005007652-A2 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286767-A1 | SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR52 | TRPV1 279/4885CFTR 1411/4885PDK1 3218/4885 |
| US-20050070547-A1 | Substituted quinolin-4-ylamine analogues | PIGS, HRH4, GPR52 | TRPV1 281/4885CFTR 1273/4885PDK1 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.